世界のオピオイド誘発性便秘市場2020-2024

◆英語タイトル:Global Opioid-Induced Constipation Market 2020-2024
◆商品コード:IRTNTR45210
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年9月22日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他の国
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、オピオイド誘発性便秘の世界市場について調査し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、投与経路別(経口、非経口)分析、薬物クラス別(末梢作用性ミューオピオイド受容体拮抗薬、局所性クロライドチャネル活性化因子)分析、顧客状況、地域別状況、企業状況、企業分析などを掲載しております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・オピオイド誘発性便秘の世界市場規模:投与経路別(経口、非経口)
・オピオイド誘発性便秘の世界市場規模:薬物クラス別(末梢作用性ミューオピオイド受容体拮抗薬、局所性クロライドチャネル活性化因子)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Opioid-Induced Constipation Market 2020-2024
Technavio has been monitoring the opioid-induced constipation market and it is poised to grow by $ 3.39 bn during 2020-2024, progressing at a CAGR of 21% during the forecast period. Our reports on the opioid-induced constipation market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increase in opioid prescriptions globally, a rise in the geriatric population, and the availability of reimbursements for opioid-based medications. In addition, an increase in opioid prescriptions globally is anticipated to boost the growth of the market as well.
The opioid-induced constipation market analysis includes the route of administration segment, class of drug, and geographical landscapes.

Technavio’s opioid-induced constipation market is segmented as below:
By Route of Administration
• Oral
• Parenteral

By Class of Drugs
• Peripherally acting mu-opioid receptor antagonists
• Locally acting chloride channel activator
• Others

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies the rise in the incidence of chronic diseases such as arthritis, back pain, and migraine as one of the prime reasons driving the opioid-induced constipation market growth during the next few years. Also, market dominance by opioid receptor antagonists and the introduction of separate diagnostic guidelines for idiopathic or functional constipation and opioid-induced constipation will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the opioid-induced constipation market covers the following areas:
• Opioid-induced constipation market sizing
• Opioid-induced constipation market forecast
• Opioid-induced constipation market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading opioid-induced constipation market vendors that include AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Also, the opioid-induced constipation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/opioid-induced-constipation-market-industry-analysis Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by route of administration
o Market segments
o Comparison by route of administration
o Oral – Market size and forecast 2019-2024
o Parenteral – Market size and forecast 2019-2024
o Market opportunity by route of administration
• Market Segmentation by class of drugs
o Peripherally acting mu-opioid receptor antagonists
o Locally acting chloride channel activator
o Other drugs
• Customer landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AstraZeneca Plc
o Bausch Health Companies Inc.
o Daiichi Sankyo Co. Ltd.
o Ironwood Pharmaceuticals Inc.
o Mallinckrodt Plc
o Merck & Co. Inc.
o Novartis AG
o Pfizer Inc.
o SHIONOGI Co. Ltd.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Key Finding 9
• 9: Parent market
• 10: Market characteristics
• 11: Offerings of vendors included in the market definition
• 12: Market segments
• 13: Global – Market size and forecast 2019 – 2024 ($ million)
• 14: Global market: Year-over-year growth 2019 – 2024 (%)
• 15: Five forces analysis 2019 & 2024
• 16: Bargaining power of buyers
• 17: Bargaining power of suppliers
• 18: Threat of new entrants
• 19: Threat of substitutes
• 20: Threat of rivalry
• 21: Market condition – Five forces 2019
• 22: Other1 – Market share 2019-2024 (%)
• 23: Comparison by Other1
• 24: Oral – Market size and forecast 2019-2024 ($ million)
• 25: Oral – Year-over-year growth 2019-2024 (%)
• 26: Parenteral – Market size and forecast 2019-2024 ($ million)
• 27: Parenteral – Year-over-year growth 2019-2024 (%)
• 28: Market opportunity by Other1
• 29: Other2 – Market share 2019-2024 (%)
• 30: Comparison by Other2
• 31: Peripherally acting mu-opioid receptor antagonists – Market size and forecast 2019-2024 ($ million)
• 32: Peripherally acting mu-opioid receptor antagonists – Year-over-year growth 2019-2024 (%)
• 33: Locally acting chloride channel activator – Market size and forecast 2019-2024 ($ million)
• 34: Locally acting chloride channel activator – Year-over-year growth 2019-2024 (%)
• 35: Others – Market size and forecast 2019-2024 ($ million)
• 36: Others – Year-over-year growth 2019-2024 (%)
• 37: Market opportunity by Other2
• 38: Customer landscape
• 39: Market share by geography 2019-2024 (%)
• 40: Geographic comparison
• 41: North America – Market size and forecast 2019-2024 ($ million)
• 42: North America – Year-over-year growth 2019-2024 (%)
• 43: Europe – Market size and forecast 2019-2024 ($ million)
• 44: Europe – Year-over-year growth 2019-2024 (%)
• 45: Asia – Market size and forecast 2019-2024 ($ million)
• 46: Asia – Year-over-year growth 2019-2024 (%)
• 47: ROW – Market size and forecast 2019-2024 ($ million)
• 48: ROW – Year-over-year growth 2019-2024 (%)
• 49: Key leading countries
• 50: Market opportunity by geography ($ million)
• 51: Impact of drivers and challenges
• 52: Vendor landscape
• 53: Landscape disruption
• 54: Industry risks
• 55: Vendors covered
• 56: Market positioning of vendors
• 57: AstraZeneca Plc – Overview
• 58: AstraZeneca Plc – Product and service
• 59: AstraZeneca Plc – Key offerings
• 60: AstraZeneca Plc – Key customers
• 61: AstraZeneca Plc – Segment focus
• 62: Bausch Health Companies Inc. – Overview
• 63: Bausch Health Companies Inc. – Business segments
• 64: Bausch Health Companies Inc. – Key offerings
• 65: Bausch Health Companies Inc. – Key customers
• 66: Bausch Health Companies Inc. – Segment focus
• 67: Daiichi Sankyo Co. Ltd. – Overview
• 68: Daiichi Sankyo Co. Ltd. – Business segments
• 69: Daiichi Sankyo Co. Ltd. – Key offerings
• 70: Daiichi Sankyo Co. Ltd. – Key customers
• 71: Daiichi Sankyo Co. Ltd. – Segment focus
• 72: Ironwood Pharmaceuticals Inc. – Overview
• 73: Ironwood Pharmaceuticals Inc. – Business segments
• 74: Ironwood Pharmaceuticals Inc. – Key offerings
• 75: Ironwood Pharmaceuticals Inc. – Key customers
• 76: Ironwood Pharmaceuticals Inc. – Segment focus
• 77: Mallinckrodt Plc – Overview
• 78: Mallinckrodt Plc – Business segments
• 79: Mallinckrodt Plc – Key offerings
• 80: Mallinckrodt Plc – Key customers
• 81: Mallinckrodt Plc – Segment focus
• 82: Merck & Co. Inc. – Overview
• 83: Merck & Co. Inc. – Business segments
• 84: Merck & Co. Inc. – Key offerings
• 85: Merck & Co. Inc. – Key customers
• 86: Merck & Co. Inc. – Segment focus
• 87: Novartis AG – Overview
• 88: Novartis AG – Business segments
• 89: Novartis AG – Key offerings
• 90: Novartis AG – Key customers
• 91: Novartis AG – Segment focus
• 92: Pfizer Inc. – Overview
• 93: Pfizer Inc. – Business segments
• 94: Pfizer Inc. – Key offerings
• 95: Pfizer Inc. – Key customers
• 96: Pfizer Inc. – Segment focus
• 97: SHIONOGI Co. Ltd. – Overview
• 98: SHIONOGI Co. Ltd. – Business segments
• 99: SHIONOGI Co. Ltd. – Key offerings
• 100: SHIONOGI Co. Ltd. – Key customers
• 101: SHIONOGI Co. Ltd. – Segment focus
• 102: Takeda Pharmaceutical Co. Ltd. – Overview
• 103: Takeda Pharmaceutical Co. Ltd. – Product and service
• 104: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 105: Takeda Pharmaceutical Co. Ltd. – Key customers
• 106: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 107: Currency conversion rates for US$
• 108: Research Methodology
• 109: Validation techniques employed for market sizing
• 110: Information sources
• 111: List of abbreviations



【掲載企業】

AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のオピオイド誘発性便秘市場2020-2024]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆